.35 semaglutide 1.75mg Semaglutide Dosing for Weight Loss:

PAI-1 modulation

Note on the three items below (GHRP-6, Melanotan 2, Snap-8)

patients should be counseled to report symptoms such as neck mass, dysphagia, or persistent hoarseness Contraindication : Personal or family history of MTC or MEN2 Gallbladder disease : Tirzepatide may increase risk of gallstones and cholecystitis Acute kidney injury : Dehydration from gastrointestinal adverse effects may impair renal function Pancreatitis : Patients should be counseled to report severe, persistent abdominal pain Niacin-specific safety concerns: Hepatotoxicity : Baseline liver function tests and monitoring during dose titration and periodically thereafter are recommended

Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity Hilary Brueck (2023)

Report persistent or severe symptoms to your prescriber right away